Rating to Follow: AstraZeneca PLC (ADR) (NYSE:AZN) Gets Vote of Confidence From Liberum Capital. What to Expect?

November 25, 2016 - By Nellie Frank

Rating to Follow:  AstraZeneca PLC (ADR) (NYSE:AZN) Gets Vote of Confidence From Liberum Capital. What to Expect?

AstraZeneca PLC (ADR) (NYSE:AZN) Upgrade

In a a research report revealed on Friday morning, Liberum Capital boosted shares of AstraZeneca PLC (ADR) (NYSE:AZN) to a Buy rating from Hold rating.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. $50 is the highest target while $32 is the lowest. The $38.40 average target is 41.70% above today’s ($27.1) stock price. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Overweight” rating given on Tuesday, December 1 by Morgan Stanley. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Buy” rating by Cantor Fitzgerald on Friday, February 26. As per Tuesday, March 15, the company rating was downgraded by Jefferies. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Underperform” rating given on Tuesday, October 20 by Credit Suisse. The stock has “Buy” rating given by Bryan Garnier & Cie on Friday, September 18. The firm has “Buy” rating by HSBC given on Wednesday, September 2. Argus Research upgraded the shares of AZN in a report on Monday, August 29 to “Buy” rating. Swedbank upgraded AstraZeneca plc (ADR) (NYSE:AZN) on Friday, July 31 to “Buy” rating. The firm has “Market Perform” rating given on Monday, May 2 by Leerink Swann. On Monday, September 14 the stock rating was upgraded by Deutsche Bank to “Buy”.

The stock increased 2.77% or $0.73 during the last trading session, hitting $27.1. About 9.57 million shares traded hands or 33.85% up from the average. AstraZeneca plc (ADR) (NYSE:AZN) has declined 12.39% since April 22, 2016 and is downtrending. It has underperformed by 17.80% the S&P500.

Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on February, 2. They expect $0.57 EPS, down 39.36% or $0.37 from last year’s $0.94 per share. AZN’s profit will be $1.43B for 11.89 P/E if the $0.57 EPS becomes a reality. After $1.32 actual EPS reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -56.82% negative EPS growth.

AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of $67.92 billion. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 27.82 P/E ratio. The Firm has its activities in over 100 countries.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Another recent and important AstraZeneca plc (ADR) (NYSE:AZN) news was published by Businessfinancenews.com which published an article titled: “AstraZeneca plc (ADR): What Are the Future Prospects?” on August 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags:

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>